XML 49 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Business Segment and Geographical Information (Tables)
 12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information Business Segment Information
(In millions)202220212020
Revenues
Life Sciences Solutions
$13,532 $15,631 $12,168 
Analytical Instruments
6,624 6,069 5,124 
Specialty Diagnostics
4,763 5,659 5,343 
Laboratory Products and Biopharma Services
22,511 14,862 12,245 
Eliminations
(2,515)(3,010)(2,662)
Consolidated revenues
44,915 39,211 32,218 
Segment Income
Life Sciences Solutions
5,582 7,817 6,109 
Analytical Instruments
1,507 1,197 808 
Specialty Diagnostics
1,024 1,280 1,368 
Laboratory Products and Biopharma Services
2,872 1,844 1,271 
Subtotal reportable segments
10,985 12,138 9,556 
Cost of revenues adjustments
(46)(8)(6)
Selling, general and administrative expenses adjustments
(37)(144)10 
Restructuring and other costs
(114)(197)(99)
Amortization of acquisition-related intangible assets
(2,395)(1,761)(1,667)
Consolidated operating income
8,393 10,028 7,794 
Interest income272 43 65 
Interest expense(726)(536)(553)
Other income/(expense)
(104)(694)(76)
Consolidated income before taxes
$7,835 $8,841 $7,230 
Depreciation
Life Sciences Solutions
$214 $197 $140 
Analytical Instruments
83 83 76 
Specialty Diagnostics
75 128 100 
Laboratory Products and Biopharma Services
614 423 342 
Consolidated depreciation
$986 $831 $658 
Cost of revenues charges included in the above table consist of charges for the sale of inventories revalued at the date of acquisition, inventory write-downs associated with large-scale abandonments of product lines, and accelerated depreciation on fixed assets to estimated salvage value in connection with the consolidation of operations. Selling, general and administrative charges/credits included in the above table consist of significant transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges/credits related to product liability litigation.
(In millions)202220212020
Total assets
Life Sciences Solutions
$21,848 $22,751 $20,209 
Analytical Instruments
10,019 9,692 9,773 
Specialty Diagnostics
5,542 6,010 6,534 
Laboratory Products and Biopharma Services
51,281 52,639 22,711 
Corporate/other (a)
8,464 4,031 9,825 
Consolidated total assets
$97,154 $95,123 $69,052 
Capital expenditures
Life Sciences Solutions
$490 $810 $392 
Analytical Instruments
140 79 74 
Specialty Diagnostics
112 167 175 
Laboratory Products and Biopharma Services
1,403 1,327 772 
Corporate/other
98 140 61 
Consolidated capital expenditures
$2,243 $2,523 $1,474 
(a)Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices.
Schedule of Revenue by Geographical Areas
Geographical Information
(In millions)202220212020
Revenues (b)
United States
$23,820 $18,907 $16,435 
China
3,793 3,444 2,797 
Other
17,302 16,860 12,986 
Consolidated revenues
$44,915 $39,211 $32,218 
Long-lived Assets (c)
United States
$6,308 $5,578 $3,686 
Other
4,565 4,286 3,001 
Consolidated long-lived assets
$10,873 $9,864 $6,687 
(b)Revenues are attributed to countries based on customer location.
(c)Includes property, plant and equipment, net, and operating lease ROU assets.